University of Pittsburgh.
Clin J Oncol Nurs. 2022 Apr 1;26(2):198-203. doi: 10.1188/22.CJON.198-203.
In metastatic breast cancer (MBC), positive estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status allow for more long-term, sequential treatment options compared to ER-negative and HER2-negative diseases. It is unclear if end-of-life care (timely integration of palliative care, discontinuation of chemotherapy, and enrollment into hospice) in MBC is now tailored to the ER and HER2 status.
This article explores the association between ER and HER2 status and the quality of end-of-life care received among patients with MBC.
A 20-year MBC clinical database captured demographics, tumor characteristics, and treatment histories of deceased patients with MBC (N = 1,258) at a tertiary hospital located in Pittsburgh, Pennsylvania. Descriptive and inferential statistics were used.
Patients with ER-positive MBC had greater odds of receiving quality end-of-life care than those with ER-negative MBC. HER2 status was not associated with differences in the quality of end-of-life care.
在转移性乳腺癌（MBC）中，阳性雌激素受体（ER）和人表皮生长因子受体 2（HER2）状态与 ER 阴性和 HER2 阴性疾病相比，允许更多长期的序贯治疗选择。目前尚不清楚 MBC 中的临终关怀（姑息治疗的及时整合、化疗的停止以及进入临终关怀）是否根据 ER 和 HER2 状态进行了调整。
本文探讨了 ER 和 HER2 状态与 MBC 患者临终关怀质量之间的关系。
宾夕法尼亚州匹兹堡的一家三级医院的 20 年 MBC 临床数据库记录了死亡 MBC 患者（N=1258）的人口统计学、肿瘤特征和治疗史。使用描述性和推断性统计。
与 ER 阴性 MBC 患者相比，ER 阳性 MBC 患者接受高质量临终关怀的可能性更大。HER2 状态与临终关怀质量无差异相关。
